Latest Ask the Experts

Biomarker Assays for Prostate Cancer Management

Should biomarker assays be an integral part of prostate cancer patient care?

Focal Therapy for Prostate Cancer: An Update

What are the major challenges regarding focal therapy for prostate cancer?

The New mCRPC Drugs

What have you learned about the differences in tolerability of the newer agents, adverse event profiles, and cost?

Latest Prostate Cancer News

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.

Not All High-Risk Prostate Cancers Are the Same

Not All High-Risk Prostate Cancers Are the Same

Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.

Positive Lymph Node Prostate Cancer Care Patterns Characterized

Positive Lymph Node Prostate Cancer Care Patterns Characterized

63% of patients were managed initially with observation.

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.

Top Complaint After Prostate Biopsy Is Infection

Top Complaint After Prostate Biopsy Is Infection

Most common infection in prostate biopsy was E. coli, followed by mild bleeding.

Vascular Targeted Photodynamic Tx Tied to Good Outcomes in Low-Risk PCa

Vascular Targeted Photodynamic Tx Tied to Good Outcomes in Low-Risk PCa

Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.

Vasectomy Poses Minimal Risk of Prostate Cancer

Vasectomy Poses Minimal Risk of Prostate Cancer

Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.

RP for Prostate Cancer May Not Offer Survival Advantage

RP for Prostate Cancer May Not Offer Survival Advantage

Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.

Sign up for free e-Newsletters